Andrew Friedberg

Andrew Friedberg, PhD, is an experienced advisor in the biopharmaceutical industry, currently serving as an Advisor at Bluestar BioAdvisors, LLC, and previously at Ionis Pharmaceuticals, Inc. Andrew's extensive background includes roles at Jazz Pharmaceuticals, where Andrew held positions such as Executive Director, Oncology Global Program Lead, and Senior Director, New Product Planning, significantly contributing to product strategy and leading successful initiatives, including the Phase III trial of Xywav. Prior experience includes serving as Director at Navigant Consulting Limited, focusing on rare diseases and oncology, as well as engagement management at Easton Associates, which emphasized life sciences consulting. Andrew's academic credentials include a PhD in Molecular and Cell Biology from UT Southwestern Medical Center and a BA in Biology from Reed College.